Review



multivariable linear probability models  (STATA Corporation)


Bioz Verified Symbol STATA Corporation is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99

    Structured Review

    STATA Corporation multivariable linear probability models
    Multivariable Linear Probability Models, supplied by STATA Corporation, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/multivariable linear probability models/product/STATA Corporation
    Average 99 stars, based on 1 article reviews
    multivariable linear probability models - by Bioz Stars, 2026-04
    99/100 stars

    Images



    Similar Products

    99
    STATA Corporation multivariable linear probability models
    Multivariable Linear Probability Models, supplied by STATA Corporation, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/multivariable linear probability models/product/STATA Corporation
    Average 99 stars, based on 1 article reviews
    multivariable linear probability models - by Bioz Stars, 2026-04
    99/100 stars
      Buy from Supplier

    90
    STATA Corporation multivariate linear probability models
    Trends in Adjusted Annual Rates of Discontinuation from LTOT from 2012 to 2017. For each year, the rate of discontinuation from LTOT is shown for LTOT users who initiated opioid therapy in the prior calendar year and whose 12-month follow-up period began at some point in the calendar year. The number in parentheses under each calendar year indicates the total number of LTOT users who initiated therapy in the prior year. For example, the 2012 cohort includes the 57,579 LTOT users who initiated their opioid therapy in 2011 with a follow-up period occurring some time in 2012. The sample size in 2017 is smaller because there are fewer LTOT users who initiated therapy early enough (i.e., in quarter 1 of 2016) to have a 1-year follow-up period in 2017. Rates of LTOT discontinuation were estimated using <t>multivariate</t> linear probability models, controlling for age, sex, race/ethnicity, state, original reason for Medicare enrollment, Medicaid enrollment, Medicare Advantage enrollment, diagnosis of chronic non-cancer pain, rurality, and total number of chronic conditions. Error bars indicate 95% CI.
    Multivariate Linear Probability Models, supplied by STATA Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/multivariate linear probability models/product/STATA Corporation
    Average 90 stars, based on 1 article reviews
    multivariate linear probability models - by Bioz Stars, 2026-04
    90/100 stars
      Buy from Supplier

    Image Search Results


    Trends in Adjusted Annual Rates of Discontinuation from LTOT from 2012 to 2017. For each year, the rate of discontinuation from LTOT is shown for LTOT users who initiated opioid therapy in the prior calendar year and whose 12-month follow-up period began at some point in the calendar year. The number in parentheses under each calendar year indicates the total number of LTOT users who initiated therapy in the prior year. For example, the 2012 cohort includes the 57,579 LTOT users who initiated their opioid therapy in 2011 with a follow-up period occurring some time in 2012. The sample size in 2017 is smaller because there are fewer LTOT users who initiated therapy early enough (i.e., in quarter 1 of 2016) to have a 1-year follow-up period in 2017. Rates of LTOT discontinuation were estimated using multivariate linear probability models, controlling for age, sex, race/ethnicity, state, original reason for Medicare enrollment, Medicaid enrollment, Medicare Advantage enrollment, diagnosis of chronic non-cancer pain, rurality, and total number of chronic conditions. Error bars indicate 95% CI.

    Journal: Journal of General Internal Medicine

    Article Title: Abrupt Discontinuation of Long-term Opioid Therapy Among Medicare Beneficiaries, 2012–2017

    doi: 10.1007/s11606-020-06402-z

    Figure Lengend Snippet: Trends in Adjusted Annual Rates of Discontinuation from LTOT from 2012 to 2017. For each year, the rate of discontinuation from LTOT is shown for LTOT users who initiated opioid therapy in the prior calendar year and whose 12-month follow-up period began at some point in the calendar year. The number in parentheses under each calendar year indicates the total number of LTOT users who initiated therapy in the prior year. For example, the 2012 cohort includes the 57,579 LTOT users who initiated their opioid therapy in 2011 with a follow-up period occurring some time in 2012. The sample size in 2017 is smaller because there are fewer LTOT users who initiated therapy early enough (i.e., in quarter 1 of 2016) to have a 1-year follow-up period in 2017. Rates of LTOT discontinuation were estimated using multivariate linear probability models, controlling for age, sex, race/ethnicity, state, original reason for Medicare enrollment, Medicaid enrollment, Medicare Advantage enrollment, diagnosis of chronic non-cancer pain, rurality, and total number of chronic conditions. Error bars indicate 95% CI.

    Article Snippet: For our main outcome of discontinuation, we used multivariate linear probability models to estimate adjusted rates of discontinuation annually, controlling for all available patient characteristics with robust standard errors clustered at the patient level using the margins command in Stata (v. 15).

    Techniques: Biomarker Discovery